¼¼°èÀÇ ½ÉºÎÀü POC ¹× LOC ±â±â ½ÃÀå
Heart Failure POC and LOC Devices
»óǰÄÚµå : 1781239
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 387 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,180,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,541,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

½ÉºÎÀü POC ¹× LOC ±â±â ¼¼°è ½ÃÀåÀº 2030³â±îÁö 2¾ï 1,480¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 9,920¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ½ÉºÎÀü POC ¹× LOC ±â±â ¼¼°è ½ÃÀåÀº 2024-2030³â ºÐ¼® ±â°£¿¡ CAGR 13.7%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 2¾ï 1,480¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ´Ü¹éÁúü °Ë»ç À¯ÇüÀº CAGR 14.3%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 1¾ï 3,360¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´ë»çü °Ë»ç À¯ÇüÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 12.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 2,700¸¸ ´Þ·¯, Áß±¹Àº CAGR 18.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½ÉºÎÀü POC ¹× LOC ±â±â ½ÃÀåÀº 2024³â¿¡ 2,700¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 4,600¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 18.4%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 10.0%¿Í 12.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 10.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ½ÉºÎÀü POC ¹× LOC ±â±â ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

½ÉºÎÀü °ü¸®¿¡¼­ POC ¹× LOC ±â±â°¡ Áß¿äÇÑ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

½ÉºÎÀüÀº ¿©ÀüÈ÷ Àü ¼¼°è ÀÌȯÀ²°ú »ç¸Á·üÀÇ ÁÖ¿ä ¿øÀÎÀ¸·Î, ½Å¼ÓÇÑ Áø´Ü ¹× ¸ð´ÏÅ͸µ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÇöÀå Áø·á(POC) ¹× ·¦¿ÂĨ(LOC) ±â±â´Â ½Ç½Ã°£ ºÐ»êÇü °Ë»ç¸¦ Á¦°øÇÏ°í ±âÁ¸ ½ÇÇè½Ç Áø´Ü¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³·ÃãÀ¸·Î½á ½ÉºÎÀü °ü¸®ÀÇ ÇÙ½É ±â¼ú·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀÌ ±â±âµéÀº BÇü ³ªÆ®·ý ÀÌ´¢ ÆéŸÀ̵å(BNP)¿Í Æ®·ÎÆ÷´Ñ°ú °°Àº ¹ÙÀÌ¿À¸¶Ä¿¸¦ Á¶±â¿¡ °¨ÁöÇÒ ¼ö ÀÖ¾î Àǻ簡 ½ÉÀå ±â´É°ú Áúº´ ÁøÇàÀ» º¸´Ù È¿À²ÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÀÀ±Þ ÇöÀåÀ̳ª Áø·á¼Ò, ¶Ç´Â ÀÚÅÿ¡¼­ Áï½Ã ±× ÀÚ¸®¿¡¼­ °Ë»çÇÒ ¼ö ÀÖ°Ô µÊ¿¡ µû¶ó ´ëÀÀ ½Ã°£ÀÌ Å©°Ô °³¼±µÇ¾î Á¶±â °³ÀÔ°ú ȯÀÚ ¿¹ÈÄ °³¼±À¸·Î À̾îÁ³½À´Ï´Ù. ¶ÇÇÑ, ¸¸¼º ½ÉÀåÁúȯ, »ýȰ½À°ü °ü·Ã À§Çè¿äÀÎÀÇ Áõ°¡, °í·ÉÈ­·Î ÀÎÇØ Á¢±Ù¼º, È޴뼺, ºñ¿ë È¿À²¼ºÀÌ ³ôÀº ½ÉÀå ¸ð´ÏÅ͸µ µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÇコÄÉ¾î »ê¾÷ÀÌ ¿¹¹æ ÀÇ·á¿Í ¸ÂÃãÇü ÀÇ·á·Î ÀüȯÇÏ´Â °¡¿îµ¥, POC ¹× LOC ±â±â´Â ½ÉºÎÀü Áø´Ü¿¡ ÀÖ¾î Çõ½ÅÀûÀÎ ¿ªÇÒÀ» ¼öÇàÇÏ¿© ½Ç½Ã°£ ȯÀÚ ¸ð´ÏÅ͸µÀ» º¸´Ù Çö½ÇÀûÀ̰í È¿°úÀûÀ¸·Î ¸¸µé°í ÀÖ½À´Ï´Ù.

¹Ì¼¼À¯Ã¼, AI, IoT´Â ¾î¶»°Ô ½ÉºÎÀü POC ¹× LOC ±â±â¸¦ °­È­ÇÒ °ÍÀΰ¡?

¹Ì¼¼À¯Ã¼, ÀΰøÁö´É(AI), »ç¹°ÀÎÅͳÝ(IoT)ÀÇ ÅëÇÕÀº ½ÉºÎÀü POC ¹× LOC ±â±âÀÇ ±â´É¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ¹Ì¼¼À¯Ã¼ ·¦¿ÂĨ ±â¼úÀº ÃÖ¼ÒÇÑÀÇ Ç÷¾×À̳ª Ÿ¾×À¸·Î Á¤È®ÇÑ ½Ã·á ºÐ¼®ÀÌ °¡´ÉÇÏ¿© ħ½ÀÀû ½Ã¼úÀÇ Çʿ伺À» ÁÙ¿©ÁÝ´Ï´Ù. AI ±â¹Ý Áø´Ü ¾Ë°í¸®ÁòÀº °Ë»ç °á°úÀÇ ÆÐÅÏÀ» ºÐ¼®Çϰí ȯÀÚÀÇ º´·Â°ú ¿¬°ü½ÃÄÑ ¹ÙÀÌ¿À¸¶Ä¿ °ËÃâÀÇ Á¤È®µµ¸¦ ³ôÀÔ´Ï´Ù. ½É¹Ú¼ö, Ç÷¾Ð, ü¾× ÀúÀå·®À» Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â IoT Áö¿ø ¿þ¾î·¯ºí ¹ÙÀÌ¿À¼¾¼­´Â ȯÀÚÀÇ ½ÉÇ÷°ü °Ç°­ »óŸ¦ ½Ç½Ã°£À¸·Î ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¿³ØÆ¼µå ±â±â¸¦ ÅëÇØ ÀÇ·áÁøÀº ¿ø°ÝÀ¸·Î ȯÀÚ¸¦ ÃßÀûÇϰí, ÀÌ»ó ¡Èİ¡ ¹ß°ßµÇ¸é ¾Ë¸²À» ¹Þ¾Æ Àû±ØÀûÀÎ °³ÀÔÀ» ÇÒ ¼ö ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý µ¥ÀÌÅÍ ÅëÇÕÀ» ÅëÇØ ÀÇ·á ½Ã½ºÅÛ °£ÀÇ ¿øÈ°ÇÑ Áø´Ü Á¤º¸ Àü´ÞÀ» º¸ÀåÇϰí, ¿¬°èµÈ Áø·á¿Í ÀÇ»ç°áÁ¤À» °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿ø°Ý ¸ð´ÏÅ͸µ°ú ¿ø°ÝÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÌ·¯ÇÑ ±â¼ú ¹ßÀüÀº ½ÉºÎÀü °ü¸®¸¦ º¸´Ù ¿¹ÃøÀûÀÌ°í °³º°È­ÇÏ¿© º´¿ø ÀçÀÔ¿øÀ» ÁÙÀ̰í Àüü »ýÁ¸À²À» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

½ÉºÎÀüÁõ¿¡ ´ëÇÑ POC ¹× LOC ±â±â µµÀÔ¿¡ ¾î¶² À庮ÀÌ Àִ°¡?

½ÉºÎÀü POC ¹× LOC ±â±â´Â ¸¹Àº ÀåÁ¡ÀÌ ÀÖÁö¸¸, ¸î °¡Áö À庮ÀÌ º¸±ÞÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä °úÁ¦ Áß Çϳª´Â ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ̸ç, ½ÉÀå Áø´Ü¾àÀº Á¤È®¼º, ½Å·Ú¼º, ¾ÈÀü¼ºÀ» º¸ÀåÇϱâ À§ÇØ ¾ö°ÝÇÑ °ËÁõÀÌ ÇÊ¿äÇÕ´Ï´Ù. FDA³ª EMA¿Í °°Àº ±â°üÀ¸·ÎºÎÅÍ ±ÔÁ¦ ´ç±¹ÀÇ Çã°¡¸¦ ¹Þ´Â °úÁ¤Àº ½Ã°£ÀÌ ¿À·¡ °É¸®¸ç, Çõ½ÅÀûÀÎ ±â±âÀÇ ½ÃÀå ÁøÀÔÀ» Áö¿¬½Ã۰í ÀÖ½À´Ï´Ù. ÷´Ü ¹Ì¼¼À¯Ã¼ ¹× AI¸¦ žÀçÇÑ Áø´Ü µµ±¸´Â ¿¬±¸°³¹ß ¹× Á¦Á¶¿¡ ¸¹Àº ÅõÀÚ°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ µµÀÔ¿¡ µå´Â ºñ¿ëµµ ¹®Á¦ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, ½Ç½Ã°£ ȯÀÚ ¸ð´ÏÅ͸µÀ» À§Çؼ­´Â ¿øÈ°ÇÑ µ¥ÀÌÅÍ ÅëÇÕÀÌ ÇʼöÀûÀ̱⠶§¹®¿¡ ±âÁ¸ ÀüÀڰǰ­±â·Ï(EHR) ¹× ÇコÄÉ¾î ½Ã½ºÅÛ°úÀÇ »óÈ£¿î¿ë¼º È®º¸°¡ ¿©ÀüÈ÷ °úÁ¦·Î ³²¾ÆÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±âÁ¸ Áø´Ü ¹æ¹ýÀÌ ¿©ÀüÈ÷ ½ÃÀåÀ» µ¶Á¡Çϰí Àֱ⠶§¹®¿¡ POC ¹× LOC ±â±âÀÇ ÀåÁ¡¿¡ ´ëÇÑ ÀÓ»óÀÇ¿Í È¯ÀÚÀÇ ÀνÄÀ» Á¦°íÇÒ Çʿ䰡 ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °úÁ¦¸¦ ±Øº¹Çϱâ À§Çؼ­´Â ÀÇ·á±â±â Á¦Á¶¾÷ü, ±ÔÁ¦ ±â°ü, ÀÇ·á ¼­ºñ½º Á¦°øÀÚ°¡ Çù·ÂÇÏ¿© º¸´Ù Æø³ÐÀº Á¢±Ù¼º°ú äÅÃÀ» º¸ÀåÇØ¾ß ÇÕ´Ï´Ù.

½ÉºÎÀü POC ¹× LOC ±â±â ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº?

½ÉºÎÀü POC ¹× LOC ±â±â ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº ½ÉÇ÷°üÁúȯÀÇ ºÎ´ã Áõ°¡, ¹Ì¼¼À¯Ã¼°øÇÐ ¹× ¹ÙÀÌ¿À¼¾¼­ ±â¼úÀÇ ¹ßÀü, ¿ø°ÝÀÇ·á ¼­ºñ½ºÀÇ È®´ëÀÔ´Ï´Ù. ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í Á¶±â ¹ß°ß ¹× ¿¹¹æ ÀÇ·á·ÎÀÇ ÀüȯÀº ½Å¼ÓÇÏ°í ºÐ»êµÈ Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀçÅà ¸ð´ÏÅ͸µ°ú ¿ø°Ý ȯÀÚ °ü¸®¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ÈÞ´ë¿ë ¹× Âø¿ëÇü ½ÉºÎÀü ¸ð´ÏÅ͸µ ±â±âÀÇ Ã¤ÅÃÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ½ÉÇ÷°ü °ü·Ã ÀÔ¿ø ¹× ÀÇ·áºñ Àý°¨À» À§ÇÑ Á¤ºÎÀÇ ³ë·Âµµ ½ÃÀå È®´ë¿¡ Å« ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ±â¼úÀÇ ¹ßÀü°ú ÇÔ²² ½ÉºÎÀü POC ¹× LOC ±â±â ½ÃÀåÀº ¼ºÀåÇϰí, Àü ¼¼°è ½ÉÇ÷°üÁúȯÀÇ Áø´Ü ¹× °ü¸® ¹æ½Ä¿¡ Çõ¸íÀ» °¡Á®¿Ã °ÍÀÔ´Ï´Ù.

ºÎ¹®

°Ë»ç À¯Çü(´Ü¹éÁúüÇÐ °Ë»ç À¯Çü, ´ë»çüÇÐ °Ë»ç À¯Çü, À¯Àüü °Ë»ç À¯Çü), ±â¼ú(¹Ì¼¼À¯Ã¼ ±â¼ú, ¾î·¹ÀÌ ±â¹Ý ½Ã½ºÅÛ ±â¼ú, ±âŸ ±â¼ú), ÃÖÁ¾»ç¿ëÀÚ(Ŭ¸®´Ð ÃÖÁ¾»ç¿ëÀÚ, º´¿ø ÃÖÁ¾»ç¿ëÀÚ, ÀçÅà ÃÖÁ¾»ç¿ëÀÚ, º¹Áö½Ã¼³ ÃÖÁ¾»ç¿ëÀÚ, ½ÇÇè½Ç ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Heart Failure POC and LOC Devices Market to Reach US$214.8 Million by 2030

The global market for Heart Failure POC and LOC Devices estimated at US$99.2 Million in the year 2024, is expected to reach US$214.8 Million by 2030, growing at a CAGR of 13.7% over the analysis period 2024-2030. Proteomic Testing Type, one of the segments analyzed in the report, is expected to record a 14.3% CAGR and reach US$133.6 Million by the end of the analysis period. Growth in the Metabolomic Testing Type segment is estimated at 12.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$27.0 Million While China is Forecast to Grow at 18.4% CAGR

The Heart Failure POC and LOC Devices market in the U.S. is estimated at US$27.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$46.0 Million by the year 2030 trailing a CAGR of 18.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.0% and 12.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.9% CAGR.

Global Heart Failure POC and LOC Devices Market - Key Trends & Drivers Summarized

Why Are Point-of-Care and Lab-on-a-Chip Devices Critical in Heart Failure Management?

Heart failure remains a leading cause of morbidity and mortality worldwide, creating a growing need for rapid diagnostic and monitoring solutions. Point-of-care (POC) and lab-on-a-chip (LOC) devices have emerged as crucial technologies in heart failure management, offering real-time, decentralized testing and reducing reliance on traditional laboratory diagnostics. These devices enable early detection of biomarkers such as B-type natriuretic peptide (BNP) and troponin, allowing physicians to assess cardiac function and disease progression more efficiently. The ability to conduct immediate, on-site tests in emergency settings, clinics, or even at home has significantly improved response times, leading to earlier interventions and better patient outcomes. Moreover, the increasing prevalence of chronic heart disease, lifestyle-related risk factors, and aging populations has heightened the demand for accessible, portable, and cost-effective cardiac monitoring tools. As the healthcare industry shifts toward preventive care and personalized medicine, POC and LOC devices are playing a transformative role in heart failure diagnostics, making real-time patient monitoring more feasible and effective.

How Are Microfluidics, AI, and IoT Enhancing POC and LOC Devices for Heart Failure?

The integration of microfluidics, artificial intelligence (AI), and the Internet of Things (IoT) is revolutionizing heart failure POC and LOC device capabilities. Microfluidic lab-on-a-chip technology enables precise sample analysis using minimal blood or saliva, reducing the need for invasive procedures. AI-driven diagnostic algorithms enhance the accuracy of biomarker detection by analyzing patterns in test results and correlating them with patient history. IoT-enabled wearable biosensors, capable of continuously monitoring heart rate, blood pressure, and fluid retention, are providing real-time insights into a patient’s cardiovascular health. These connected devices allow healthcare providers to remotely track patients and receive alerts for any abnormalities, enabling proactive interventions. Cloud-based data integration ensures seamless transmission of diagnostic information across healthcare systems, improving coordinated care and decision-making. With the growing emphasis on remote monitoring and telehealth, these technological advancements are making heart failure management more predictive and personalized, reducing hospital readmissions and improving overall survival rates.

What Barriers Exist in the Adoption of POC and LOC Devices for Heart Failure?

While heart failure POC and LOC devices offer numerous advantages, several barriers hinder their widespread adoption. One of the primary challenges is regulatory approval, as cardiac diagnostics require stringent validation to ensure accuracy, reliability, and safety. The process of obtaining regulatory clearance from agencies like the FDA and EMA can be time-consuming, delaying the market entry of innovative devices. Another challenge is the cost of implementation, as advanced microfluidic and AI-powered diagnostic tools require significant investment in research, development, and manufacturing. Additionally, ensuring interoperability with existing electronic health records (EHRs) and healthcare systems remains a hurdle, as seamless data integration is crucial for real-time patient monitoring. There is also a need for greater clinician and patient awareness regarding the benefits of POC and LOC devices, as traditional diagnostic methods continue to dominate the market. Overcoming these challenges will require collaborative efforts between medical device manufacturers, regulatory bodies, and healthcare providers to ensure broader accessibility and adoption.

What Is Driving the Growth of the Heart Failure POC and LOC Devices Market?

The growth in the heart failure POC and LOC devices market is driven by the increasing burden of cardiovascular diseases, advancements in microfluidics and biosensor technology, and the expansion of telehealth services. Rising healthcare expenditures and the shift toward early detection and preventive care have fueled demand for rapid and decentralized diagnostic solutions. The growing focus on home-based monitoring and remote patient management has accelerated the adoption of portable and wearable heart failure monitoring devices. Government initiatives aimed at reducing cardiovascular-related hospitalizations and healthcare costs are also playing a significant role in driving market expansion. As technology continues to advance, the heart failure POC and LOC devices market is set to grow, revolutionizing how cardiovascular diseases are diagnosed and managed worldwide.

SCOPE OF STUDY:

The report analyzes the Heart Failure POC and LOC Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Proteomic Testing Type, Metabolomic Testing Type, Genomic Testing Type); Technology (Microfluidics Technology, Array-based Systems Technology, Other Technologies); End-Use (Clinics End-Use, Hospitals End-Use, Home End-Use, Assisted Living Healthcare Facilities End-Use, Laboratory End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â